To evaluate the long-term safety and efficacy of posterior chamber collagen copolymer phakic intraocular lens (pIOL) implantation to correct myopia.
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Today, phakic intraocular lenses (pIOLs) are usually implanted as an alternative treatment to correct ametropia of various refractive ranges. An evolving technique in the field of refractive surgery, pIOL implantation has several advantages, including fast visual recovery, excellent refractive accuracy and stability, improved visual acuity, preservation of accommodation, and reversibility.
At present, the Visian Implantable Collamer Lens pIOL (Staar Surgical Co.) is the only posterior chamber pIOL approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe myopia. This pIOL is of a foldable collagen copolymer material and is designed to be placed in the posterior chamber, behind the iris, with a haptic zone resting on the ciliary sulcus. Several studies report its effectiveness in correcting myopia, [1] [2] [3] [4] [5] hyperopia, 6, 7 and astigmatism [8] [9] [10] or in patients who may not be appropriate candidates for corneal reshaping procedures. [11] [12] [13] [14] However, in addition to the risks of any intraocular surgery, 15 the main concerns with pIOL implantation relate to its long-term safety, including long-term endothelial cell loss, 16, 17 pigmentary glaucoma, 18 pupillary block, 19, 20 and cataract formation. 21 Although studies of pIOL implantation report acceptable complication and visual acuity loss rates, few studies have spanned more than 3 years to observe the long-term clinical and refractive outcomes. 22, 23 Long-term potential problems cannot be dismissed because the risk for them may increase with time. The aim of the present study was to evaluate the long-term (up to 5 years) clinical and refractive outcomes of pIOL implantation to correct moderate to high myopia.
PATIENTS AND METHODS
This retrospective observational study included the medical records of patients who had implantation of a Visian Implantable Collamer Lens pIOL for myopia correction at Fern andez-Vega Ophthalmological Institute, Oviedo, Spain, between December 2001 and January 2007 and regularly returned for evaluations for at least 3 years postoperatively. At the time of the surgery, all patients were fully informed of the details and possible risks of the surgical procedure. Written informed consent was obtained from all patients before surgery in accordance with the Declaration of Helsinki, and an institutional review board approved the study.
The inclusion criteria for pIOL implantation were a corrected distance visual acuity (CDVA) of 20/50 or better, stable refraction, and a clear central cornea. The exclusion criteria included age younger than 22 years, anterior chamber depth (ACD) less than 2.8 mm, endothelial cell density (ECD) less than 2000 cells/mm 2 , cataract, history of glaucoma or retinal detachment, macular degeneration or retinopathy, neuro-ophthalmic disease, and a history of ocular inflammation.
Before pIOL implantation, patients had a complete ophthalmologic examination including manifest and cycloplegic refractions, keratometry, corneal topography and pachymetry (Orbscan II, Bausch & Lomb), ECD (SP 3000P, Topcon Europe Medical), slitlamp examination, Goldmann applanation tonometry, and binocular indirect ophthalmoscopy through dilated pupils. Cell counts were performed in a semiautomatic manner by the same technician. After automatic cell detection by the instrument, the technician corrected the edges of cells that had not been identified by the fully automatic image analysis. This ensured higher reliability of image analysis. 24, 25 A minimum of 100 cells was required in each image to process the cell counting.
Phakic Intraocular Lens Size and Power Calculation
The Visian Implantable Collamer Lens pIOL for myopia is rectangular and 7.0 mm wide. It is available in 4 overall lengths (11.5 mm, 12.0 mm, 12.5 mm, 13.0 mm) and a dioptric power range of À3.00 to À23.00 diopters (D). In all cases, a model ICL V4 pIOL was implanted and the target was emmetropia (when possible). The pIOL size was determined based on the horizontal white-to-white (WTW) distance and ACD, measured with the Orbscan II device following the manufacturer's recommendations; that is, the size was calculated by adding 0.5 mm to the horizontal WTW measurement. Power calculation for the pIOL was performed using the modified vertex formula in the power-table software provided by the manufacturer. The pIOL implantation technique has been described. 26, 27 Follow-up Postoperative follow-up visits were at 1 day; 1 week; 1, 3, and 6 months; and 1 year and then yearly thereafter. Uncorrected distance visual acuity (UDVA), CDVA, slitlamp examination, refraction, ECD, fundus examination, and intraocular pressure (IOP) were performed at each visit. For averaging, visual acuities were converted to logMAR values; then, the means and standard deviations (SDs) were back-calculated to Snellen acuity. The central separation between the anterior surface of the crystalline lens and the posterior surface of the pIOL (vault) was first assessed using an optical section during routine slitlamp examination. Vault was classified in 5 levels by comparing the separation between the anterior surface of the crystalline lens and the posterior surface of the pIOL with the central corneal thickness (CCT). 26 A few years after the first pIOLs were implanted, vault was also assessed using optical coherence tomography (OCT) (Visante, Carl Zeiss Meditec AG). In this method, the vault was measured perpendicular to the lens apex or at the narrowest space between both surfaces. The percentage of ECD loss was determined as follows: endothelial cell loss (%) Z (preoperative ECD À postoperative ECD)/preoperative ECD.
Statistical Analysis
Data analysis was performed using SPSS for Windows software (version 16.01, SPSS, Inc.). Normality of data was checked by the Kolmogorov-Smirnov test and analyzed using the paired t test, Wilcoxon rank-sum test, or analysis of variance with multiple comparisons, where appropriate, to determine statistical differences for refractive, visual, and adverse outcomes. Differences were considered statistically significant when the P value was less than 0.05.
RESULTS
This study cohort comprised 188 eyes of 111 patients, of which 80 (72%) were women. Table 1 shows the preoperative demographic data of the patients and the pIOL characteristics. 
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MYOPIC PIOL IMPLANTATION: 5-YEAR FOLLOW-UP consecutive intervals through 5 years, the total 5-year loss was 7.7% ( Figure 6 ).
The mean IOP was 13.9 G 1.8 mm Hg preoperatively and 13.8 G 1.5 mm Hg 5 years postoperatively. There were no statistically significant differences in mean IOP between visits (PO.05, paired sample t test).
The mean postoperative vault assessed at the slitlamp was 2.4 G 1.0 at 1 month and 2.0 G 0.7 at 5 years. The mean vault measured with OCT was 410 G 228 mm (95% CI, 361 to 459), 354 G 166 mm (95% CI, 296 to 412), and 364 G 198 mm (95% CI, 294 to 434) at 3 years, 4 years, and 5 years, respectively; there were no statistically significant differences in the mean vault between follow-up visits (PZ.325, ANOVA).
Adverse Events and Secondary Surgery
There were no intraoperative complications, and no eye required pIOL explantation or repositioning. One eye developed a clinically significant symptomatic anterior subcapsular cataract 35.7 months after pIOL implantation. The 40-year-old patient had a preoperative SE of À13.50 D and a CDVA of 20/40; 1 month after pIOL implantation, the SE was C0.25 D and the UDVA was 20/32. Three years after surgery, the eye lost 2 lines of CDVA and the vault was 180 mm. Simultaneous phacoemulsification, pIOL extraction, and Acri.Smart 366 IOL (Acri.Tech GmbH) implantation was successfully performed. After cataract surgery, the UDVA was 20/40, the CDVA was 20/32, and the SE was À0.75 D.
Two eyes developed an asymptomatic anterior subcapsular cataract 27.4 and 55.2 months, respectively, after pIOL implantation. Both eyes lost 1 line of CDVA over the preoperative value but had 20/25 CDVA at the last follow-up visit. Although neither eye required cataract surgery, the patients were scheduled for closer follow-up.
No pigmentary glaucoma, pupillary block, or other vision-threatening complications occurred at any time during the follow-up; however, 3 eyes had a mild transient increase in IOP (up to 27 mm Hg) during the first 3 months.
DISCUSSION
Most studies of pIOL implantation report short-term clinical outcomes (up to 1 or 2 years), and few have spanned 3 or more years to allow observation of the long-term clinical and refractive results. 1, 22, 23 In the present study, we confirmed the very good results in all measures of safety, efficacy, predictability, and stability of Visian Implantable Collamer Lens pIOL implantation to correct moderate to high myopia throughout a 5-year follow-up. The outcomes were consistent between patients and between follow-up visits, with most eyes maintaining or improving CDVA and no eye losing more than 2 lines. The safety index was higher than 1.18 at all postoperative visits. There was also an improvement in UDVA; more than 30% of eyes achieved a UDVA of 20/20 or better at all follow-up visits, and the mean change in SE between visits was approximately 0.65 D up to 5 years.
Clinical results with the earlier version of the pIOL we evaluated in this study confirm that the implantation procedure is a feasible treatment option for various ranges of ametropia and that it gives excellent visual and refractive results, even if some complications occurred. 20, [28] [29] [30] In addition, when compared with the visual outcomes of laser keratorefractive procedures, pIOL implantation seems to provide better visual performance with equal or better efficacy and safety. [31] [32] [33] [34] [35] In a 3-year FDA myopic Implantable Collamer Lens study of 526 eyes of 294 patients, 1 94.7% of patients had a UDVA of 20/40 or better, 67.5% were within G0.50 D of the predicted refraction, and 88.2% were within G1.00 D of the predicted refraction. The mean improvement in CDVA was between 0.5 lines and 0.6 lines. Three eyes (0.8%) had a decrease in CDVA of 2 lines, 15 eyes (2.9%) required an additional refractive procedure, 14 eyes (2.7%) developed early asymptomatic anterior subcapsular cataract, and 3 eyes (0.6%) required pIOL removal with cataract extraction and IOL implantation.
Lackner et al., 22 . In that study, 11 eyes (14.5%) developed lens opacification that was significantly progressive in 5 eyes, probably as a result of surgical trauma and older age.
In a study by Kamiya et al. 23 of 56 eyes of 34 patients (mean SE À9.8 G 3.0 D; range À4.00 to À15.25 D), the mean UDVA and CDVA improved from 1.49 G 0.22 logMAR and À0.15 G 0.08 logMAR, respectively, preoperatively to À0.03 G 0.23 and À0.21 G 0.09, respectively, 4 years after surgery. Five eyes (9%) lost 1 line of CDVA; no eye lost 2 or more lines. Fortyfour eyes (79%) were within G0.50 D of the attempted correction, and 52 eyes (93%) were within G1.00 D. The mean percentage of endothelial cell loss was 3.7% 4 years after surgery.
The results in the present study are comparable to those previously reported. In our study, 70.0% (35/50) of eyes achieved a CDVA of 20/25 or better 5 years after surgery. The greatest loss of CDVA was 2 lines in 1 eye that developed a clinically significant symptomatic anterior subcapsular cataract. Regarding refractive outcomes, a smaller proportion of eyes in this study than in previous studies were within G0.50 D and G1.00 D of the attempted correction; this is because 9.0% of eyes (17/188) in our study had a preoperative SE higher than À15.00 D and 8.5% (16/188) had refractive cylinder of 2.00 D or higher that could not be fully corrected by the strongest available pIOL power. These cases were targeted for undercorrection. However, the correlation between the attempted refraction and the achieved refraction was high, with 82.6% (152/184) of eyes and 62.0% (31/50) of eyes being within G1.00 D of the desired refraction at 3 years and 5 years, respectively. The SE was also stable throughout the followup, with a slight tendency toward a myopic shift. The shift might be explained by the biometric changes that occur in myopic patients 36 or by the decrease in vault, 27 narrowing the gap between the pIOL and the crystalline lens and increasing the effective power of the optical system. The most significant concern about pIOL implantation is cataract formation. In the Implantable Collamer Lens FDA trial, 1 the rate of cataract formation was 2.1%. Other studies report a secondary cataract formation rate between 1.6% 37 and 14.5%. 22 In a 5-year follow-up study by Sanders, 21 anterior subcapsular opacities occurred in 5.9% of 526 eyes, with 1.3% progressing to clinically significant cataract; progression to clinically significant cataract generally occurred in patients with very high myopia or in older patients. In a study by Alfonso et al. 27 of 964 myopic eyes of 531 patients, anterior subcapsular cataract developed in 13 eyes (1.3%); the cataract developed before 1 year in 2 eyes, between 2 years and 3 years in 7 eyes, and after 3 years in 4 eyes, indicating that patient age and lower vault are the most important factors in pIOL-induced cataract. In a recent metaanalysis by Chen et al. 38 of 6338 eyes that included anglesupported, iris-supported, and posterior chamber pIOLs, the incidence of cataract formation in eyes with the Implantable Collamer Lens pIOL (1933 eyes; 218 V2 or earlier models, 249 V3 models, 877 V4 models, and 589 design not specified) was 8.48%. Early cataract formation was related to surgical trauma and late cataract formation, to pIOL-crystalline lens contact.
In the present study, 3 eyes (1.6%) developed late anterior subcapsular cataract. The cataract was clinically significant in 1 case, leading to pIOL removal and phacoemulsification with IOL implantation. This eye was highly myopic (À13.50 D) and had a vault of 180 mm 3 years after surgery. In the other 2 eyes with anterior subcapsular cataract, the loss of CDVA was 1 Snellen line and there was no need for a second surgery, although the patients were scheduled for closer follow-up. The main theories of the cause of late anterior subcapsular cataract development are absent or lower vault and the tendency of the vault to decrease slightly over time, causing constant or intermittent pIOL-crystalline lens contact. 27, 39, 40 A limitation of our study was that it was not possible to measure vault objectively with OCT from the first day after pIOL implantation; thus, we could not objectively measure the changes in vault over time. However, the mean vault assessed at the slitlamp and compared with CCT decreased slightly over time (mean vault level 2.4 G 1.0 at 1 month and 2.0 G 0.7 at 5 years), which was confirmed with OCT (mean vault 410 G 228 mm at 3 years and 364 G 198 mm at 5 years).
Another limitation of our study is the small number of patients who completed the 5-year follow-up. Most patients were lost to follow-up between the 4-year and 5-year visits, with 184 eyes (97.9%) available for the 3-year visit. This is usual with successful treatments such as pIOL implantation because patients who are satisfied with the outcomes often do not return for the recommended regular visits. Although this may have had some impact on the final results, a higher follow-up rate would likely improve the results in areas such as efficacy, predictability, safety, and vault. A significant decrease in vault can cause changes in visual acuity and in the worst cases, cataract formation. Thus, we believe that a better follow-up rate would have improved our results. Although our results match well with those in previous studies with a similar sample size, this limitation does have some implications. For example, the trend toward regression in myopia over time (mean 0.88 D at 5 years) might be because more patients with regression than patients who had no change in refraction attended the follow-up visits.
Endothelial cell loss is another concern with pIOL implantation. The rate of postoperative endothelial cell loss has been reported to be approximately 6.5% at 2 years 28 and 6.09% at 3 years. 41 Others report a mean endothelial cell loss of 3.7% at 4 years. 23 In the FDA clinical study, Edelhauser et al. 17 found a cumulative endothelial cell loss between 8.4% and 8.9% over the first 3 years and between 8.4% and 9.5% over the first 4 years, with an endothelial cell loss rate of 2% to 3% per year over the first 3 years of follow-up. There was a 0.1% increase in cells between 3 years and 4 years, suggesting that endothelial remodeling and stability may have been achieved by 3 years. We found a mean endothelial cell loss of approximately 1.5% per year and a mean cumulative endothelial cell loss of 7.7% at 5 years. The ongoing cell loss was more noticeable during the first year (5.5%), after which it decreased and stabilized. The percentage of ECD loss with age is reported to be 0.5 to 0.6 per year. 42, 43 Thus, our results may be explained by corneal remodeling after the surgical procedure rather than by continuing cell loss due to the effect of aging.
Another important concern after pIOL implantation is increased IOP, which in most cases is associated with significant angle narrowing by forward iris displacement 44 or with chronic pigment dispersion. 18 In the present study, 3 eyes (1.6%) had a mild transient increase in IOP (up to 27 mm Hg); the eyes had between 15.00 D and 17.00 D of preoperative myopia and had high initial pIOL vault; none of those eyes needed a second surgical procedure or prolonged topical medication.
In summary, our long-term results suggest that Visian Implantable Collamer Lens pIOL implantation to correct moderate to high myopia is a safe and effective procedure that provides predictable and stable refractive results over the long term; in this case, over 5 years. The rates of postoperative complications were low, and there were no vision-threatening complications throughout the follow-up. Future studies with a longer follow-up are necessary to assess lateonset complications, specifically in the development of anterior lens opacities and the change in vault over time.
